Zināšanu bāze

Vispirms paskaidrojam, tad pārdodam.

Faktiskas, ar avotiem pamatotas piezīmes par mūsu pārdotajiem savienojumiem un to, kā tie tiek pārbaudīti. Tikai pētniecības konteksts - bez devu, lietošanas vai veselības norādījumiem.

Regulatory · 6 minThe 2025-2026 incretin approvals, and where research compounds sitThree GLP-1 drugs cleared the FDA in seven months. What was approved, and how investigational compounds like retatrutide differ.Lasīt →Compound · 7 minRetatrutide: a triple receptor agonist in Phase 3What retatrutide is at the molecular level, what its TRIUMPH trials reported, and why it is still investigational.Lasīt →Compound · 6 minMOTS-c: a mitochondria-derived signalling peptideA peptide written into the mitochondrial genome, why it is called an exercise mimetic, and what recent studies examined.Lasīt →Quality · 5 minWhat “≥99 % purity” actually meansA purity number is only meaningful with its method and its batch. Here is what the figure includes - and what it does not.Lasīt →Handling · 4 minLyophilised peptides and temperatureWhy freeze-dried powder is stable, how it is stored, and when stability is lost. Storage facts only - no reconstitution or usage instructions.Lasīt →Methods · 5 minHPLC and LC-MS: two different questionsOne method tells you how much is there; the other tells you whether it is the right molecule. Why a report uses both.Lasīt →